Articles

O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

BJH - volume 7, issue Abstract Book BHS, january 2016

R. Heusschen PhD, J. Muller MSc, M. Binsfeld , E. Plougonven , N. Mahli , G. Carmeliet , A. Léonard , prof. F. Baron , M. Cohen-Solal , K. Vanderkerken PhD, Y. Beguin MD, PhD, E. Menu , J. Caers MD, PhD

Read more

P1.01 Myeloid Derived Suppressor Cells induce Multiple Myeloma cell survival through AMPK activation

BJH - volume 6, issue Abstract Book BHS, january 2015

K. De Veirman , J. van Ginderachter , N. De Beule MD, PhD, S. Lub , A. Maes , E. De Bruyne , E. Menu , I. Van Riet PhD, K. Vanderkerken PhD, E. Van Valckenborgh PhD

Read more

P1.02 In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma

BJH - volume 6, issue Abstract Book BHS, january 2015

dr. K. Maes , E. De Smedt , A. Kassambara , D. Hose , A. Seckinger , E. Van Valckenborgh PhD, E. Menu , B. Klein , K. Vanderkerken PhD, J. Moreaux , E. De Bruyne

Read more

Biological properties of mesenchymal stem cells in the multiple myeloma tumour microenvironment

BJH - volume 5, issue 2, june 2014

X. Song MD, PhD, K. Vanderkerken PhD, I. Van Riet PhD

Summary

Mesenchymal stem cells are multipotent non-hematopoietic progenitor cells that are capable of differentiating into various mesenchymal tissues and give rise to most bone marrow stromal cells. Several studies have demonstrated that bone marrow derived mesenchymal stem cells from multiple myeloma patients are functionally and genetically abnormal compared to their normal counterparts. However, the direct involvement of mesenchymal stem cells in the pathophysiology of multiple myeloma remains unclear. In our research project we aimed to investigate how mesenchymal stem cells influence multiple myeloma cell growth and whether and at which level the differentiation of mesenchymal stem cells towards osteoblasts is impaired in this disease. Our data provided evidence that mesenchymal stem cells can stimulate tumour growth and disease evolution in multiple myeloma and are involved in the bone disease associated with this malignancy.

(BELG J HEMATOL 2014;5(2):64–7)

Read more

O.5 In vivo gene expression profiling in the murine 5T33MM model identifies epigenetic-regulated genes predictive for prognosis and drug-sensitivity

BJH - volume 5, issue Abstract Book BHS, january 2014

dr. K. Maes , E. De Smedt , D. Hose , E. Van Valckenborgh PhD, E. Menu , B. Klein , K. Vanderkerken PhD, J. Moreaux , E. De Bruyne

Read more

P2.16 Activation of invariant natural killer T cells reduces angiogenesis in the 5T33 multiple myeloma model

BJH - volume 5, issue Abstract Book BHS, january 2014

H. Nur , L. Rao , A. Vacca , D. Elewaut , E. Van Valckenborgh PhD, E. De Bruyne , K. Vanderkerken PhD, E. Menu

Read more

P3.02 Bone Marrow Stromal Cell-derived Exosomes Facilitate Multiple Myeloma Cell Survival Through Inhibition of the JNK Pathway

BJH - volume 5, issue Abstract Book BHS, january 2014

J. Wang , A. Hendrix , E. De Bruyne , E. Van Valckenborgh PhD, E. Himpe , B. De Beule , O. De Wever , K. Vanderkerken PhD, E. Menu

Read more